Home › Funds › LOOMIS SAYLES & CO L P › ALNY

LOOMIS SAYLES & CO L P position in ALNY

ALNYLAM PHARMACEUTICALS INC · Health Care

LOOMIS SAYLES & CO L P reported holding 580,187 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$174.7M, representing 0.22% of its reported portfolio and ranking #50 among its reported holdings. LOOMIS SAYLES & CO L P has disclosed ALNY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)580.19K sh
Reported value held$174.65M
Portfolio Weight0.22%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How LOOMIS SAYLES & CO L P's ALNY position evolved

LOOMIS SAYLES & CO L P first disclosed a stake in ALNY in Q3 2023 at 625,401 shares (US$110.8M). The position peaked in Q3 2025 at 500,672 shares, worth US$228.3M. Across 12 filings, LOOMIS SAYLES & CO L P increased the stake 3 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 580,187 shares valued at US$174.7M — an increase of 63,230 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 625.40K $110.76M New
Q4 2023 608.73K $116.52M Reduce
Q1 2024 581.85K $86.96M Reduce
Q2 2024 569.28K $138.34M Reduce
Q3 2024 525.30K $144.47M Reduce
Q4 2024 503.05K $118.37M Reduce
Q1 2025 498.08K $134.49M Reduce
Q2 2025 487.33K $158.91M Reduce
Q3 2025 500.67K $228.31M Add
Q4 2025 497.94K $198.01M Reduce
Q1 2026 516.96K $171.05M Add
Q2 2026 580.19K $174.65M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ALNY and 13F data

ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 35 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$734.5M), Orbis Allan Gray Ltd (US$598.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ALNY

All ALNY fund holders →

FAQ

How long has LOOMIS SAYLES & CO L P held ALNY?

LOOMIS SAYLES & CO L P has disclosed ALNY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is LOOMIS SAYLES & CO L P's current position in ALNY?

As of Q2 2026, LOOMIS SAYLES & CO L P holds 580.19K shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $174.65M, representing 0.22% of its reported portfolio and ranking #50.

Has LOOMIS SAYLES & CO L P been buying or selling ALNY?

In the latest 13F filing (Q2 2026), LOOMIS SAYLES & CO L P increased its position in ALNY. The position peaked in Q3 2025 at 500.67K shares.

Which other funds hold ALNY?

Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.